These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 6631916

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.
    Manning M, Nawrocka E, Misicka A, Olma A, Klis WA, Seto J, Sawyer WH.
    J Med Chem; 1984 Apr; 27(4):423-9. PubMed ID: 6708045
    [Abstract] [Full Text] [Related]

  • 3. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
    Manning M, Kruszynski M, Bankowski K, Olma A, Lammek B, Cheng LL, Klis WA, Seto J, Haldar J, Sawyer WH.
    J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
    [Abstract] [Full Text] [Related]

  • 4. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.
    Manning M, Olma A, Klis WA, Kolodziejczyk AM, Seto J, Sawyer WH.
    J Med Chem; 1982 Jan; 25(1):45-50. PubMed ID: 7086821
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
    Manning M, Lammek B, Bankowski K, Seto J, Sawyer WH.
    J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M, Cheng LL, Stoev S, Bankowski K, Przybyiski J, Klis WA, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1995 Oct; 1(1):66-79. PubMed ID: 9222985
    [Abstract] [Full Text] [Related]

  • 8. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M, Cheng LL, Stoev S, Klis W, Nawrocka E, Olma A, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1997 Oct; 3(1):31-46. PubMed ID: 9230469
    [Abstract] [Full Text] [Related]

  • 9. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
    Manning M, Misicka A, Olma A, Klis WA, Bankowski K, Nawrocka E, Kruszynski M, Kolodziejczyk A, Cheng LL, Seto J.
    J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
    Manning M, Cheng LL, Klis WA, Balaspiri L, Olma A, Sawyer WH, Wo NC, Chan WY.
    J Med Chem; 1995 May 12; 38(10):1762-9. PubMed ID: 7752199
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
    Stoev S, Cheng LL, Olma A, Klis WA, Manning M, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1999 Mar 12; 5(3):141-53. PubMed ID: 10323558
    [Abstract] [Full Text] [Related]

  • 14. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.
    Manning M, Przybylski J, Grzonka Z, Nawrocka E, Lammek B, Misicka A, Cheng LL, Chan WY, Wo NC, Sawyer WH.
    J Med Chem; 1992 Oct 16; 35(21):3895-904. PubMed ID: 1433200
    [Abstract] [Full Text] [Related]

  • 15. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M, Stoev S, Cheng LL, Wo NC, Chan WY.
    J Pept Sci; 2001 Sep 16; 7(9):449-65. PubMed ID: 11587184
    [Abstract] [Full Text] [Related]

  • 16. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
    Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY.
    Int J Pept Protein Res; 1995 Sep 16; 46(3-4):244-52. PubMed ID: 8537178
    [Abstract] [Full Text] [Related]

  • 17. Design of potent antagonists of the vasopressor response to arginine-vasopressin.
    Bankowski K, Manning M, Haldar J, Sawyer WH.
    J Med Chem; 1978 Sep 16; 21(9):850-3. PubMed ID: 722751
    [Abstract] [Full Text] [Related]

  • 18. Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin.
    Manning M, Klis WA, Kruszynski M, Przybylski JP, Olma A, Wo NC, Pelton GH, Sawyer WH.
    Int J Pept Protein Res; 1988 Dec 16; 32(6):455-67. PubMed ID: 3246475
    [Abstract] [Full Text] [Related]

  • 19. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.
    J Pept Sci; 2006 Mar 16; 12(3):190-8. PubMed ID: 16130178
    [Abstract] [Full Text] [Related]

  • 20. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.
    J Med Chem; 2004 Apr 22; 47(9):2375-88. PubMed ID: 15084136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.